Date: 2018-02-21
Type of information: Development agreement
Compound: innovative therapies
Company: Arix Bioscience (UK) Ipsen (France)
Therapeutic area: undisclosed
Type agreement: development - commercialisation
Action mechanism:
Disease: undisclosed
Details:
- • On February 21, 2018, Arix Bioscience , a global healthcare and life science company supporting medical innovation, and Ipsen announced a strategic agreement to develop and commercialise innovative therapies.
- Arix will provide Ipsen with access to its unique network of professional and scientific advisors, and the chance to invest in opportunities in Arix’s new and existing businesses. In return, Ipsen will contribute research, development and commercial expertise to the partnership. Arix and Ipsen will collaborate to identify opportunities and jointly create new companies focused primarily on the development and commercialisation of innovative therapies for patients.
- Arix made investments into 13 innovative life science companies in 2016 and 2017, with multiple value-creating milestones expected over the next 18 months. Arix expects to continue to build on its already rich pipeline to provide funding andexpertise to additional new businesses in 2018.
Financial terms:
Latest news:
Is general: Yes
